Francesco Orio

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6763229/publications.pdf

Version: 2024-02-01

31 papers	2,615 citations	201385 27 h-index	395343 33 g-index
33 all docs	33 docs citations	33 times ranked	2861 citing authors

#	Article	IF	Citations
1	Early Impairment of Endothelial Structure and Function in Young Normal-Weight Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4588-4593.	1.8	310
2	The Cardiovascular Risk of Young Women with Polycystic Ovary Syndrome: An Observational, Analytical, Prospective Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3696-3701.	1.8	250
3	The Increase of Leukocytes as a New Putative Marker of Low-Grade Chronic Inflammation and Early Cardiovascular Risk in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2-5.	1.8	212
4	High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer, 2002, 95, 1076-1084.	2.0	155
5	Adiponectin Levels in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2619-2623.	1.8	148
6	Improvement in Endothelial Structure and Function after Metformin Treatment in Young Normal-Weight Women with Polycystic Ovary Syndrome: Results of a 6-Month Study. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6072-6076.	1.8	129
7	Low vitamin D status and obesity: Role of nutritionist. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 215-225.	2.6	116
8	Exon 6 and 2 Peroxisome Proliferator-Activated Receptor-Î³ Polymorphisms in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5887-5892.	1.8	106
9	Homocysteine Levels and C677T Polymorphism of Methylenetetrahydrofolate Reductase in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 673-679.	1.8	85
10	Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). Clinical Endocrinology, 2008, 69, 792-798.	1.2	85
11	Bisphenol <scp>A</scp> in polycystic ovary syndrome and its association with liverâ€“spleen axis. Clinical Endocrinology, 2013, 78, 447-453.	1.2	79
12	Circulating Ghrelin Concentrations in the Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 942-945.	1.8	76
13	Nutrition, inflammation and liver-spleen axis. Critical Reviews in Food Science and Nutrition, 2018, 58, 3141-3158.	5.4	74
14	Cardiopulmonary Impairment in Young Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2967-2971.	1.8	70
15	Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?. Reproductive BioMedicine Online, 2004, 9, 505-510.	1.1	66
16	Endocrine Aspects of Environmental â€œObesogenâ€•Pollutants. International Journal of Environmental Research and Public Health, 2016, 13, 765.	1.2	63
17	Cardiovascular risk in women with polycystic ovary syndrome. Fertility and Sterility, 2006, 86, S20-S21.	0.5	58
18	Lack of an Association between Peroxisome Proliferator-Activated Receptor-Î³ Gene Pro12Ala Polymorphism and Adiponectin Levels in the Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5110-5115.	1.8	54

#	Article	IF	Citations
19	Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells. Scientific World Journal, The, 2014, 2014, 1-13.	0.8	54
20	Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. Journal of Translational Medicine, 2011, 9, 136.	1.8	53
21	Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies. Human Reproduction, 2003, 18, 1410-1416.	0.4	48
22	New guidelines for the diagnosis and treatment of PCOS. Nature Reviews Endocrinology, 2014, 10, 130-132.	4.3	48
23	Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women. Clinical Endocrinology, 2008, 68, 976-981.	1.2	45
24	Expertsâ€™ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 255-274.	1.5	45
25	Endocrine disorders during the first year after autologous stem-cell transplant. American Journal of Medicine, 2005, 118, 664-670.	0.6	42
26	Inositols in the Treatment of Insulin-Mediated Diseases. International Journal of Endocrinology, 2016, 2016, 1-6.	0.6	42
27	Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. European Journal of Endocrinology, 2007, 157, 69-73.	1.9	41
28	Reproductive issues in patients undergoing Hematopoietic Stem Cell Transplantation: an update. Journal of Ovarian Research, 2016, 9, 72.	1.3	27
29	GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome. Journal of Endocrinological Investigation, 2003, 26, 117-122.	1.8	11
30	Lack of electrocardiographic changes in women with polycystic ovary syndrome. Clinical Endocrinology, 2007, 67, 46-50.	1.2	5
31	Letter to the Editor: Vitamin D: A Wonder Drug for the Cure of Type 2 Diabetes?. Journal of Clinical Endocrinology and Metabolism, 2016, 101, L43-L44.	1.8	3